Table of Contents Table of Contents
Previous Page  15 / 60 Next Page
Information
Show Menu
Previous Page 15 / 60 Next Page
Page Background

13

PROGRAMME & EXHIBITION GUIDE |

SCIENTIFIC PROGRAMME

14:25 A randomised trial of concomitant cisplatin-RT +/- induction TPF in

locally advanced nasopharyngeal carcinomas

J. Daoud, A. Aupérin, Y.G. Tao, P. Lang, X.S. Sun, S. Racadot, J. Thariat, M.

Alfonsi, C. Tuchais, A. Moussai, A. Cornely, J. Bourhis (France)

OC-004

14:35 Discussant: B. O’Sullivan (Canada)

14:40 Afatinib versus methotrexate in recurrent/metastatic HNSCC after plati-

num therapy: LUX-head and neck 1

P. Clement (Belgium), T. Gauler, J.P.H. Machiels, R. Haddad, J. Fayette, L.F.

Licitra, M. Tahara, J.B. Vermorken, D. Cupissol, J.J. Grau, J. Guigay, F. Capo-

nigro, G. de Castro Jr, L. De Souza Viana, U. Keilholz, J.M. Del Campo, X.J.

Cong, L. Svensson, E. Ehrnrooth, E.E.W. Cohen, On behalf of the LUX-head

and neck 1 investigators

OC-005

14:50 Concomitant treatment (CRT or cetuximab/RT) with or without induction

TPF in locally advanced head and neck cancer

M.G. Ghi (Italy), A. Paccagnella, D. Ferrari, P. Foa, M. Cossu Rocca, E. Verri,

F. Morelli, G. Azzarello, C. D’Ambrosio, C. Casanova, M. Guaraldi, E. Massa,

C. Rossetto, A. Bonetti, S. Siena, A. Frattegiani, H. Koussis, G. Pieri, A. Gava,

I. Floriani, for the GSTTC Italian Study Group

OC-006

15:00 Discussant: J. Vermorken (Belgium)

15:05 Is accelerated radiotherapy alone equivalent to chemo-radiation in patients

with moderate advanced HNSCC?

K. Skladowski (Poland), A. Wygoda, M. Snetura, T. Rutkowski, L. Michalecki,

A. Heyda, A. Hajduk, M. Kentnowski, B. Lukaszczyk-Widel, B. Maciejewski

OC-007

15:15 POPART vs CPORT in squamous cell head and neck cancer: Results of a

multicenter randomised study of the Dutch head and neck study group

H. Langendijk (The Netherlands), J.H. Kaanders, P. Doornaert, F.R. Burlage,

P.L.A. Van den Ende, S.B. Oei, R.B. Keus, S. Nuyts, R. Leemans, H. Van

Tinteren, C.H. Terhaard

OC-008

15:35 Update of the randomised phase III trial DAHANCA 19: Primary C-RT or

RT and zalutumumab for squamous cell carcinomas of head and neck

J.G. Eriksen (Denmark), C. Maare, J. Johansen, H. Primdahl, J. Evensen, C.A.

Kristensen, L.J. Andersen, J. Overgaard

OC-009

15:45 Discussant: W. Budach (Germany)